What is ALLR's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.02B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ALLR?

P/E (TTM) is n/a and 52-week range is $0.77 to $1.84 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ALLR figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ALLR?

The company profile lists net income (TTM) near $-13M, EPS (TTM) near $-0.79 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Allarity Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Boston, Massachusetts, US, 15.9M shares outstanding, ISIN US0167445008 when available from company profile and filing metadata.

Allarity Therapeutics Inc

$ALLR

Health Care · Biotechnology

IR Run Scenarios

$0.99

+0.82%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company is headquartered in Boston, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2021-12-21. The company is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its therapeutic candidate, stenoparib, is a dual inhibitor of the key DNA damage repair enzyme PARP, as well as Tankyrases, critical enzymes involved in the WNT signaling pathway commonly activated in many cancers. Inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancers (ovarian cancers). The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes.

Employees

Website

allarity.com/

IPO

2021-12-21

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)